FDA approves Rozlytrek™ for cancer patients with ROS1-positive & NTRK
Category: #health  By Pankaj Singh  Date: 2019-08-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA approves Rozlytrek™ for cancer patients with ROS1-positive & NTRK

FDA approves Rozlytrek™ for cancer patients with ROS1-positive & NTRK

Rozlytrek™ will be Roche’s first FDA approved medicine that targets genetically mutilated cancer as well as both ROS1 and NTRK fusions.

Roche Holding AG, a Swiss pharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has given approval to Rozlytrek™ (entrectinib) to treat adults suffering from ROS1-positive, metastatic non-small cell lung cancer (NSCLC).

According to reports, the FDA has authorized Rozlytrek to treat adults and pediatric patients above 12 years of age with solid tumors that contain an NTRK (neurotrophic tyrosine receptor kinase) gene fusion with an unknown origin of resistance mutation, which is metastatic or has progressed during treatment or has no satisfactory alternative therapy.

As per reliable sources, the combined analysis of the pivotal Phase I STARTRK-1, Phase I ALKA-372-001 trials and Phase II STARTRK-2 and information from the Phase I/II STARTRK-NG study have played a significant role in getting an approval from the FDA.

In the integrated analysis, Rozlytrek was examined in various solid tumor types, including cholangiocarcinoma, breast, gynecological, colorectal, non-small cell lung, neuroendocrine, pancreatic, salivary gland, thyroid cancers and sarcoma.

However, in ROS1-positive, metastatic NSCLC, Rozlytrek reduced tumors in 78% of patients suffering from the disease and the DoR (duration of response) ranged from 1.8 to 36.8+ months. Rozlytrek also lowered tumors in more than half of patient suffering from NTRK gene fusion-positive, metastatic solid tumor or locally advanced, while objective results were witnessed across 10 types of tumor with a DoR ranging from 2.8 to 26.0+ months.

According to Sandra Horning, MD, Chief Medical Officer & Head of Global Product Development, Roche, the FDA approval for Rozlytrek for treating two key types of cancer is great news for patients. She claims that Rozlytrek is the first treatment by the company that has gained FDA’s approval for treating both NTRK fusions and ROS1, while showing significant response in rare cancer types that have reached patient’s brain.

Source Credit: https://www.globenewswire.com/news-release/2019/08/16/1902884/0/en/FDA-approves-Roche-s-RozlytrekTM-entrectinib-for-people-with-ROS1-positive-metastatic-non-small-cell-lung-cancer-and-NTRK-gene-fusion-positive-solid-tumours.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...